293 related articles for article (PubMed ID: 35311584)
1. The Effect of Vaccine Type and SARS-CoV-2 Lineage on Commercial SARS-CoV-2 Serologic and Pseudotype Neutralization Assays in mRNA Vaccine Recipients.
Tolan NV; Sherman AC; Zhou G; Nabel KG; Desjardins M; Melanson S; Kanjilal S; Moheed S; Kupelian J; Kaufman RM; Ryan ET; LaRocque RC; Branda JA; Dighe AS; Abraham J; Baden LR; Charles RC; Turbett SE
Microbiol Spectr; 2022 Apr; 10(2):e0021122. PubMed ID: 35311584
[TBL] [Abstract][Full Text] [Related]
2. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
[TBL] [Abstract][Full Text] [Related]
3. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies.
Kohmer N; Rabenau HF; Ciesek S; Krämer BK; Göttmann U; Keller C; Rose D; Blume C; Thomas M; Lammert A; Lammert A
Nephrol Dial Transplant; 2022 May; 37(6):1132-1139. PubMed ID: 35099023
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection.
Tyner HL; Burgess JL; Grant L; Gaglani M; Kuntz JL; Naleway AL; Thornburg NJ; Caban-Martinez AJ; Yoon SK; Herring MK; Beitel SC; Blanton L; Nikolich-Zugich J; Thiese MS; Pleasants JF; Fowlkes AL; Lutrick K; Dunnigan K; Yoo YM; Rose S; Groom H; Meece J; Wesley MG; Schaefer-Solle N; Louzado-Feliciano P; Edwards LJ; Olsho LEW; Thompson MG
Clin Infect Dis; 2022 Aug; 75(1):e827-e837. PubMed ID: 34928334
[TBL] [Abstract][Full Text] [Related]
5. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals.
Hayer J; Urlaub E
Microbiol Spectr; 2022 Jun; 10(3):e0270921. PubMed ID: 35575594
[TBL] [Abstract][Full Text] [Related]
7. Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity.
Kawasuji H; Morinaga Y; Tani H; Saga Y; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Niimi H; Yamamoto Y
Microbiol Spectr; 2021 Dec; 9(3):e0056121. PubMed ID: 34851162
[TBL] [Abstract][Full Text] [Related]
8. Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.
Lu L; Chen LL; Zhang RR; Tsang OT; Chan JM; Tam AR; Leung WS; Chik TS; Lau DP; Choi CY; Fong CH; Cai JP; Tsoi HW; Choi CY; Zhang X; Abdullah SMU; Chan BP; Chan KH; Yuen KY; Hung IF; To KK
EBioMedicine; 2022 May; 79():103986. PubMed ID: 35398786
[TBL] [Abstract][Full Text] [Related]
9. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
[TBL] [Abstract][Full Text] [Related]
10. Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273.
Grunau B; Golding L; Prusinkiewicz MA; Asamoah-Boaheng M; Armour R; Marquez AC; Jassem AN; Barakauskas V; O'Brien SF; Drews SJ; Haig S; Lavoie PM; Goldfarb DM
Microbiol Spectr; 2022 Apr; 10(2):e0270221. PubMed ID: 35254166
[TBL] [Abstract][Full Text] [Related]
11. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
[TBL] [Abstract][Full Text] [Related]
12. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines.
Zhang GF; Meng W; Chen L; Ding L; Feng J; Perez J; Ali A; Sun S; Liu Z; Huang Y; Guo H; Gao SJ
J Med Virol; 2022 Dec; 94(12):5678-5690. PubMed ID: 35902378
[TBL] [Abstract][Full Text] [Related]
14. Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered.
López-Cortés LF; Saborido-Alconchel A; Trujillo-Rodríguez M; Serna-Gallego A; Llaves-Flores S; Muñoz-Muela E; Pérez-Santos MJ; Lozano C; Mejias-Trueba M; Roca C; Espinosa N; Gutiérrez-Valencia A
Front Immunol; 2023; 14():1129753. PubMed ID: 37006309
[TBL] [Abstract][Full Text] [Related]
15. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
16. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
[TBL] [Abstract][Full Text] [Related]
17. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers.
Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824
[TBL] [Abstract][Full Text] [Related]
18. Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
Obeid M; Suffiotti M; Pellaton C; Bouchaab H; Cairoli A; Salvadé V; Stevenel C; Hottinger R; Pythoud C; Coutechier L; Molinari L; Trono D; Ribi C; Gottardo R; Fenwick C; Pascual M; Duchosal MA; Peters S; Pantaleo G
JAMA Oncol; 2022 May; 8(5):e220446. PubMed ID: 35271706
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.
Nickel O; Rockstroh A; Wolf J; Landgraf S; Kalbitz S; Kellner N; Borte M; Pietsch C; Fertey J; Lübbert C; Ulbert S; Borte S
PLoS One; 2022; 17(10):e0263861. PubMed ID: 36256664
[TBL] [Abstract][Full Text] [Related]
20. Comparison of humoral immunogenicity in solid organ transplant recipients after third-dose mRNA vaccine with homologous or heterologous schedules: An observational study.
Kang JM; Lee J; Huh KH; Joo DJ; Lee JG; Kim HY; Lee M; Jung I; Kim MY; Kim S; Park Y; Kim MS
J Clin Virol; 2023 Feb; 159():105374. PubMed ID: 36592547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
